Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine Smg/Sml Oral Solution

Deepthi | Myequity news | Date : 05-02-2019 15:59:00 IST

UK MHRA has granted Marketing Authorisation to Marksans Pharma Limited’s wholly owned subsidiary, Relonchem Limited, UK for Loratadine 5mg/5ml Oral Solution for the UK markets. The product will be manufactured in its UK facility. Loratadine Oral Solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children

More from Myequity